How Pre-POC Oncology Biotech Navigate

This article summarizes insights from a recent Cancer Progress Webinar Series discussion focused on how early oncology biotechs can navigate immuno-oncology fatigue, increased scrutiny of emerging modalities, geopolitical shifts, and tighter capital markets. Hosted by Lumanity and moderated by Dr. Jeff Bockman, and Dr. Viraj Parekh the panel brought together perspectives spanning scientific leadership, business development, commercialization, and global partnering to examine how focused science, credible early data, and deliberate development choices position programs to advance in a more selective market. In this environment, hope is not sentiment, it is disciplined execution. In a time of extra scrutiny for funding or partnering, not modality nor mechanism nor target are inherently differentiating, but data demonstrating a convincing value proposition for addressing unmet needs are.

Reframing the Early Oncology Landscape

The early oncology landscape is undergoing a reset. After years of exuberant funding and rapid expansion, today’s market demands sharper evidence, clearer differentiation, and disciplined execution from the very beginning. Moderator Jeff Bockman opened the session by noting how quickly expectations have shifted: even breaking geopolitical developments—like recent proposals to restrict U.S. use of China-invented medicines—now influence partnering strategies and development pathways.

Co-moderator Viraj Parekh expanded on this shift with a macro lens. The 2021 funding peak was followed by a contraction that has not rebounded evenly. Capital is available, but only for programs that can demonstrate mechanistic clarity, translational grounding, and a credible path to clinical value. The new environment leaves little room for exploratory breadth; focus and evidence now determine momentum.

This framing set up the panel’s central question: What does it take for an emerging oncology company to build a differentiated, credible program in an era where pre-POC rigor—not enthusiasm—defines who advances?

Download the full recap to see what’s changing, what it demands of the field — and how those questions are already shaping Cancer Progress 2026.